Purchase this article with an account.
S. Kandula, J. C. Lamkin, T. Albanese, D. P. Edward; Patients’ Knowledge and Perspectives on Wet Age-Related Macular Degeneration and its Treatment. Invest. Ophthalmol. Vis. Sci. 2009;50(13):252.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
In recent years there has been an increase in our understanding of wet age-related macular degeneration (ARMD), and a dramatic shift in the treatment paradigm. However, to our knowledge, no studies have examined how much ARMD patients understand their disease, or how they feel about receiving intraocular injections as treatment. The primary objectives of this study are to identify areas in which ARMD patients may be uninformed, and to recognize specific fears or expectations that patients may have regarding treatment with intraocular anti-VEGF injections.
An anonymous 32-item questionnaire was compiled and distributed to patients with wet ARMD who underwent at least one intraocular anti-VEGF injection. 83 patients from a retina practice in a suburban setting completed the questionnaire that gauged both their knowledge of ARMD and their perspectives on its treatment. Data was analyzed using Chi-Square testing.
78% of patients received most of their knowledge of ARMD from their physician. 89% of patients prefer to receive more information on ARMD, if needed, directly from their physician. Only 21%, 48%, 37%, 48%, and 36%, respectively, correctly identified how diet, special vitamins, high blood pressure, family history, and smoking can affect ARMD. 6% of patients reported pain and 22% of patients reported discomfort during the injections. 60% felt somewhat afraid or very afraid about getting their first intraocular injection, but this did not correlate with pain or discomfort during treatment (p=0.075, p=0.117). 89% were very satisfied and 11% were somewhat satisfied with the explanation their physician gave them about the injection procedure. 80% reported feeling hopeful, significantly more than any other emotion, when they were first told they needed an intraocular injection for treatment of their disease.
Knowledge of risk factors and risk factor modification among patients with ARMD is low. Since the vast majority of ARMD patients prefer to receive information directly from their physician, patient education is crucial in improving risk factor modification and alleviating fears of treatment. With the advent of anti-VEGF agents, patients appear more hopeful of regaining vision than they are fearful of treatment with intraocular injections.
This PDF is available to Subscribers Only